Physician profile
Cashawn Springer
NPI 1669291761
$1,151.17
in general payments reported to CMS, 2019-2025
20 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $207.13 | 2025 | Korlym |
| Novo Nordisk INC | $167.24 | 2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $139.45 | 2025 | |
| Harmony Biosciences LLC | $116.90 | 2025 | |
| Amgen INC. | $56.24 | 2025 | Repatha |
| Aimmune Therapeutics, INC. | $52.56 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals LP | $52.22 | 2025 | Breztri, Airsupra |
| Recordati_rare_diseases_inc. | $48.28 | 2025 | Isturisa |
| Axsome Therapeutics, INC. | $43.01 | 2025 | Auvelity, Sunosi |
| Lilly USA, LLC | $42.57 | 2025 | Mounjaro, Zepbound |
| Pfizer INC. | $42.15 | 2025 | |
| Esperion Therapeutics, INC. | $34.31 | 2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $30.53 | 2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $22.32 | 2025 | |
| Bausch Health US, LLC | $19.04 | 2025 | Wellbutrin, Aplenzin |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $18.51 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.66 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.52 | 2025 | Jardiance |
| Dexcom, INC. | $14.43 | 2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $14.10 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cashawn Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.